Decades of pharma leadership at Bristol Myers Squibb, Teva, Avet Pharma, AMRI and National Resilience — applied to the problems that matter most to pharmaceutical owners, operators and investors.
Improve throughput, OEE, quality systems and cost structure across manufacturing operations.
Capacity planning, customer mix, pricing and growth strategy for contract manufacturers.
Commercial and operational due diligence for private equity and strategic buyers.
Launching, scaling and restructuring brand and generic pharmaceutical businesses.
William S. Marth has spent three decades building and leading pharmaceutical businesses across branded, generic and contract manufacturing. He began in sales and marketing leadership at Bristol Myers Squibb, then spent 14 years at Teva, rising to President and CEO of Teva Pharmaceuticals – Americas. He went on to lead Albany Molecular Research (AMRI) through its 2017 sale to The Carlyle Group and GTCR, and later served as Global President and CEO, North America & Europe, of Avet Pharma.
Today he is President & CEO of National Resilience and Chairman of Meribel Pharma Solutions, and advises Rosemont Pharma and Lupin Manufacturing Solutions.
Through North Ocean Ventures, he helps owners, operators and investors with the decisions he has made himself: where to invest in capacity, how to fix underperforming operations, and what a pharma business is really worth.
Galmed Pharmaceuticals · Sorrento Therapeutics · Albany Molecular Research
B.S. Pharmacy, University of Illinois · MBA, Keller Graduate School of Management · Hon. Doctor of Humane Letters, Albany College of Pharmacy and Health Sciences
Tell us a little about your situation and we'll get back to you promptly.
2631 Hawks Landing Blvd, Palm Harbor, FL 34685, USA